10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $11.17 billion. The enterprise value is $10.69 billion.
| Market Cap | 11.17B |
| Enterprise Value | 10.69B |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 130.29 million shares outstanding. The number of shares has increased by 4.39% in one year.
| Current Share Class | 120.21M |
| Shares Outstanding | 130.29M |
| Shares Change (YoY) | +4.39% |
| Shares Change (QoQ) | +1.32% |
| Owned by Insiders (%) | 7.79% |
| Owned by Institutions (%) | 103.94% |
| Float | 118.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.10 |
| Forward PS | 17.27 |
| PB Ratio | 13.53 |
| P/TBV Ratio | 14.74 |
| P/FCF Ratio | 91.96 |
| P/OCF Ratio | 87.87 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 88.06 |
Financial Position
The company has a current ratio of 5.69, with a Debt / Equity ratio of 0.10.
| Current Ratio | 5.69 |
| Quick Ratio | 5.09 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.65 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -9.40% and return on invested capital (ROIC) is -5.75%.
| Return on Equity (ROE) | -9.40% |
| Return on Assets (ROA) | -5.05% |
| Return on Invested Capital (ROIC) | -5.75% |
| Return on Capital Employed (ROCE) | -8.91% |
| Weighted Average Cost of Capital (WACC) | 15.56% |
| Revenue Per Employee | $523,694 |
| Profits Per Employee | -$63,773 |
| Employee Count | 1,178 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 3.03 |
Taxes
In the past 12 months, 10x Genomics has paid $235,000 in taxes.
| Income Tax | 235,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +610.70% in the last 52 weeks. The beta is 2.08, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 2.08 |
| 52-Week Price Change | +610.70% |
| 50-Day Moving Average | 60.37 |
| 200-Day Moving Average | 32.91 |
| Relative Strength Index (RSI) | 73.93 |
| Average Volume (20 Days) | 2,816,264 |
Short Selling Information
The latest short interest is 16.69 million, so 12.81% of the outstanding shares have been sold short.
| Short Interest | 16.69M |
| Short Previous Month | 16.16M |
| Short % of Shares Out | 12.81% |
| Short % of Float | 14.12% |
| Short Ratio (days to cover) | 6.17 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $616.91 million and -$75.13 million in losses. Loss per share was -$0.59.
| Revenue | 616.91M |
| Gross Profit | 432.53M |
| Operating Income | -81.18M |
| Pretax Income | -74.89M |
| Net Income | -75.13M |
| EBITDA | -41.20M |
| EBIT | -81.18M |
| Loss Per Share | -$0.59 |
Balance Sheet
The company has $552.03 million in cash and $78.80 million in debt, with a net cash position of $473.24 million or $3.63 per share.
| Cash & Cash Equivalents | 552.03M |
| Total Debt | 78.80M |
| Net Cash | 473.24M |
| Net Cash Per Share | $3.63 |
| Equity (Book Value) | 825.55M |
| Book Value Per Share | 6.34 |
| Working Capital | 556.16M |
Cash Flow
In the last 12 months, operating cash flow was $127.09 million and capital expenditures -$5.65 million, giving a free cash flow of $121.44 million.
| Operating Cash Flow | 127.09M |
| Capital Expenditures | -5.65M |
| Depreciation & Amortization | 39.98M |
| Net Borrowing | n/a |
| Free Cash Flow | 121.44M |
| FCF Per Share | $0.93 |
Margins
Gross margin is 70.11%, with operating and profit margins of -13.16% and -12.18%.
| Gross Margin | 70.11% |
| Operating Margin | -13.16% |
| Pretax Margin | -12.14% |
| Profit Margin | -12.18% |
| EBITDA Margin | -6.68% |
| EBIT Margin | -13.16% |
| FCF Margin | 19.68% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.39% |
| Shareholder Yield | -4.39% |
| Earnings Yield | -0.67% |
| FCF Yield | 1.09% |
Analyst Forecast
The average price target for 10x Genomics is $56.60, which is -33.96% lower than the current price. The consensus rating is "Buy".
| Price Target | $56.60 |
| Price Target Difference | -33.96% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 5.07% |
| EPS Growth Forecast (3Y) | 44.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 5.75 and a Piotroski F-Score of 3.
| Altman Z-Score | 5.75 |
| Piotroski F-Score | 3 |